Free tool
FAERS Monitor: Amjevita
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming BLA 761024 or its brand name (Amjevita, Adalimumab-Atto). Reports on generic versions are filed under their own applications.
Reports
1,610
Serious
423
26% of reports
Hospitalization
152
Death reported
19
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- device difficult to use379
- product storage error280
- drug dose omission by device247
- circumstance or information capable of leading to medication error194
- accidental exposure to product164
- injection site pain125
- drug ineffective90
- wrong technique in product usage process87
- intercepted product administration error75
- pain71
- off label use68
- product communication issue68
- rheumatoid arthritis51
- arthralgia40
- device use error38
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2017 | 1 |
| 2018 | 5 |
| 2019 | 6 |
| 2020 | 15 |
| 2021 | 13 |
| 2022 | 5 |
| 2023 | 493 |
| 2024 | 433 |
| 2025 | 305 |
| 2026 | 334 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,052,549 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| intercepted product administration errorSignal | 75 | 129.0 | 103.3 | 9,313 |
| product communication issueSignal | 68 | 101.5 | 80.3 | 6,616 |
| circumstance or information capable of leading to medication errorSignal | 194 | 75.5 | 66.1 | 14,121 |
| device difficult to useSignal | 379 | 75.2 | 68.9 | 27,613 |
| product storage errorSignal | 280 | 41.9 | 37.7 | 11,153 |
| drug dose omission by deviceSignal | 247 | 41.3 | 36.8 | 9,687 |
| accidental exposure to productSignal | 164 | 20.8 | 18.0 | 3,085 |
| device use errorSignal | 38 | 14.3 | 10.4 | 457 |
| rheumatoid arthritisSignal | 51 | 5.9 | 4.5 | 202 |
| wrong technique in product usage processSignal | 87 | 5.6 | 4.6 | 328 |
| injection site painSignal | 125 | 5.3 | 4.5 | 441 |
| pain | 71 | 1.5 | 1.2 | 12 |
| arthralgia | 40 | 1.3 | 0.9 | 2 |
| off label use | 68 | 1.0 | 0.8 | 0 |
| drug ineffective | 90 | 0.9 | 0.7 | 1 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.